Latest news with #STS
Yahoo
5 days ago
- Health
- Yahoo
Society of Thoracic Surgeons launches risk calculator app
American not-for-profit organisation The Society of Thoracic Surgeons (STS) has introduced the STS Risk Calculator App, a mobile application designed to provide real-time access to its range of adult cardiac surgery and thoracic surgery risk calculators. Intended for surgeons and multidisciplinary medical professionals, the app draws on data from the STS National Database and can be accessed via iOS and Android platforms. This database is a resource containing around ten million cardiothoracic procedures carried out by more than 4,300 surgeons, utilising the same statistical models found in STS' online risk calculators. The STS Risk Calculator App is designed to be intuitive and user-friendly, allowing for quick risk evaluations at the bedside or while on the move. This real-time access to data is pivotal in supporting informed clinical decisions and enhancing the quality of care delivered to individuals. The app includes individualised risk assessments for cardiac procedures such as isolated tricuspid valve repair and replacement, and multi-valve surgery with or without coronary artery bypass grafting. It also predicts outcomes such as stroke, death, renal failure, and hospital stay periods. STS president Joseph Sabik III said: 'Having immediate access to reliable, evidence-based risk assessment tools is critical for improving surgical decision-making and patient outcomes. 'This mobile application ensures that up-to-date, risk-adjusted data is always within reach, bringing the power of the STS National Database to surgeons and care teams wherever and whenever they need it.' STS noted that the Esophagectomy Risk Calculator offers 30-day risk evaluations for oesophageal cancer patients while the Lung Cancer Resection Risk Calculator will estimate 30-day postoperative risks for lung cancer resection procedures, including segmentectomy, lobectomy, or wedge resection. "Society of Thoracic Surgeons launches risk calculator app" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Time of India
14-06-2025
- Health
- Time of India
7 research opportunities you shouldn't miss in medical college
Medical school is more than just passing exams and mastering clinical rotations—it's also the ideal time to build a strong academic and research profile. Research experience not only enhances your understanding of medicine but also adds weight to residency applications, scholarships, and future fellowships. Tired of too many ads? go ad free now Whether you're aiming for a competitive postgraduate seat or considering a non-clinical career in academia or public health, research experience can be a game-changer. Here are seven such research opportunities every medical student should seriously consider. ICMR-STS (Short Term Studentship) The Indian Council of Medical Research offers the STS program to undergraduate medical students interested in biomedical research. Conducted annually, this two-month summer project allows you to work under the guidance of a faculty mentor on a topic of your choice. If your proposal and final report are accepted, you'll also receive a stipend. ICMR-STS is highly respected and widely recognized across India, making it one of the best ways to begin your research journey. Institutional Research Projects and Mentorships Most medical colleges have active research cells or ethics committees that support undergraduate research. These internal programs can be incredibly valuable—whether it's participating in faculty-led projects, helping with data collection in clinical studies, or initiating your own research with institutional support. If your college encourages research presentations or has tie-ups with journals, you might even get a chance to publish or present your findings at conferences. International Electives and Exchange Programs Global exposure can significantly broaden your research perspective. Programs like IFMSA exchanges or elective observerships in the US, UK, or Australia allow you to be part of ongoing research abroad. These experiences not only give insight into international healthcare systems but also provide a chance to work on globally relevant research questions, often resulting in certifications or research publications. Tired of too many ads? go ad free now Summer Internships at Premier Institutes (like AIIMS, NIMHANS, PGI) Institutes such as AIIMS Delhi, PGIMER Chandigarh, and NIMHANS Bengaluru offer summer internship programs where students can work alongside experts on cutting-edge medical research. These internships are typically competitive, but they provide hands-on experience in both laboratory and clinical research environments. Some programs may also include training workshops and seminars that can add significantly to your academic development. National and State-Level Conferences Participating in medical conferences is a great way to gain exposure and network with professionals. Undergraduate conferences such as MEDICON, as well as annual meets organized by various specialty associations, provide platforms to present your work. Presenting a paper or poster at these events not only builds confidence but also enhances your academic CV. Research with NGOs and Public Health Bodies For those interested in epidemiology, public health, or social medicine, research projects with organizations like WHO, UNICEF, or national NGOs working in healthcare can be both meaningful and insightful. These projects often focus on real-world challenges such as vaccine outreach, disease surveillance, or maternal health—and can offer valuable field experience in addition to academic credit. Student Research Societies and Online Research Platforms Joining student-led research societies or online medical research platforms can open doors to collaborative projects. These communities often host online courses, competitions, and mentorship programs. Being part of such initiatives allows you to network with like-minded peers, get feedback on your research ideas, and even find long-distance mentors or co-authors. Getting involved in research during medical college may feel intimidating at first, but it doesn't have to be. Start small—assist a senior, join a faculty-led study, or attend a research workshop. Over time, you'll build the skills and confidence needed to lead your own projects. Most importantly, you'll learn to ask questions, think critically, and contribute meaningfully to the future of medicine.
Egypt Independent
13-06-2025
- Business
- Egypt Independent
Damietta Port bolsters Egypt's hub vision with 5 giant cranes for Tahya Misr 1 terminal
Lieutenant General Kamel El Wazir, Deputy Prime Minister for Industrial Development and Minister of Industry and Transport, confirmed Damietta Port's reception of the Chinese vessel ZHEN HUA 33. On board were five colossal Ship-to-Shore (STS) quay cranes, designated for the Tahya Misr 1 container terminal's berths. This delivery is part of the ongoing superstructure work being carried out by Damietta Alliance, the terminal's operator, in preparation for its imminent inauguration and operation. The arrival of these cranes marks a pivotal moment in equipping the terminal with the world's most advanced operating systems. This delivery augments a prior shipment of seven colossal STS cranes, raising the total count of sophisticated quay cranes now on site to 12. Manufactured by HHMC, a prominent Chinese leader in contemporary port equipment, these cranes possess formidable operational capabilities, including a lifting capacity of 75 tons and an impressive 57.5-meter outreach from the quay. This allows them to efficiently handle mega-vessels carrying up to 11 containers high. Furthermore, their impressive 72-meter outreach enables them to manage the widest container ships, significantly enhancing the port's capacity to accommodate the most advanced global container vessels. The new cranes are also equipped with cutting-edge safety systems, including sensors, cameras, and protection systems, to ensure safe loading and unloading operations. They also support integration with smart port management systems, enabling real-time monitoring of operational activities and achieving the highest levels of efficiency and coordination among various operating departments within the terminal. In a related development, the terminal has so far received 30 of the 40 planned environmentally friendly Rubber-Tyred Gantry (RTG) cranes. These RTG cranes are designed for high operational efficiency, standing 21 meters tall, and support a dual-power system allowing operation by either electricity or diesel, enhancing operational flexibility and efficiency under various conditions. They were manufactured by the Chinese company Genma-Kalmar, a global leader in advanced handling equipment. The Tahya Misr 1 container terminal project stands as one of the largest national endeavors currently underway at Damietta Port. Its quays stretch for 1,970 meters with a depth of 18 meters, complemented by a vast 922,000-square-meter back area. This impressive setup provides a handling capacity of up to 3.5 million TEUs (Twenty-foot Equivalent Units). Damietta Alliance Container Terminals, a consortium comprising Germany's Eurogate, Italy's Contship, and the global shipping line Hapag-Lloyd, is responsible for operating the terminal. Their management will adhere to the latest international standards, significantly bolstering the port's standing as a fully integrated logistics hub in the region. This vital project aligns with the Ministry of Transport's comprehensive plan to develop all Egyptian ports. The overarching goal is to transform Egypt into a regional hub for transport, logistics, and transit trade, in line with directives from President Abdel Fattah El-Sisi. Its implementation also falls within the framework of establishing the integrated logistical corridor (Tanta-Mansoura-Damietta). This will collectively contribute to boosting the national economy, enhancing the global competitiveness of Egyptian ports by increasing operational efficiency, reducing waiting times, and improving their capacity to accommodate the new generation of mega-ships.
Yahoo
11-06-2025
- Business
- Yahoo
Moleculin Participates in Virtual Investor 'What This Means' Segment
Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) Watch the 'What This Means" segment here HOUSTON, June 11, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it participated in a Virtual Investor 'What This Means' segment. For the segment, Brian Andrew Van Tine, MD, PhD, Professor of Medicine, Washington University School of Medicine, discussed the Company's recently announced positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases ('STS lung mets') (MB-107). The MB-107 trial was a multi-center, open-label, single-arm monotherapy study that in Phase 1B determined the Maximum Tolerable Dose and Recommended Phase 2 Dose ('MTD', 'RP2D' respectively) and safety of Annamycin and in Phase 2 explored the efficacy of Annamycin as a single agent for the treatment of subjects with STS lung mets for which chemotherapy was considered appropriate. For more information about the MB-107 trial visit and reference identifier NCT04887298. The Virtual Investor 'What This Means' segment featuring Moleculin is now available here. About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Forward-Looking StatementsSome of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the release of the initial data on the first 45 subjects in the trial and the Company's ability to reconcile the US and EU protocols with the FDA and EMA, respectively. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. 'Risk Factors' in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775MBRX@
Cision Canada
10-06-2025
- Business
- Cision Canada
Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes The ADCElerate1 trial will enroll patients in the US and Europe COPENHAGEN, Denmark, June 10, 2025 /CNW/ -- Adcendo, a clinical-stage biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that the first patient has been dosed in the Phase I/II ADCElerate1 clinical trial evaluating ADCE-D01 in patients with metastatic and/or unresectable soft tissue sarcoma (STS). The patient was dosed at The Memorial Sloan Kettering Cancer Center in New York. ADCElerate1 (NCT06797999) is a first-in-human Phase I/II multicenter, open-label, dose escalation and expansion study evaluating ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS. The primary objective of the study is to evaluate the safety and tolerability of ADCE-D01. The secondary objectives are to characterize the pharmacokinetics and to evaluate the preliminary efficacy of ADCE-D01. The study will recruit in the US and Europe with the European clinical trial application recently approved (EUCT number: 2024-516900-41-00). Dr. Lone Ottesen, Chief Medical Officer of Adcendo, said: "The dosing of the first patient in the ADCElerate1 study is a major milestone for both Adcendo and for the uPARAP program and we are excited to evaluate ADCE-D01's potential benefit for patients with advanced STS. uPARAP is a highly attractive target for the development of an ADC in mesenchymal cancers, as it is highly overexpressed in multiple STS subtypes, has unique internalization properties, and shows only very low expression in healthy tissues." Professor Robert Maki, MD, PhD, Sarcoma Oncologist and Early Drug Development Specialist at the Department Musculoskeletal Cancers and Condition, in the Memorial Sloan Kettering Cancer Center, New York, NY, commented: "We are very pleased to be working with Adcendo to develop ADCE-D01 for the many advanced STS patients who currently have very limited treatment options. ADCs have already made a significant impact across the therapeutic landscape, and we are pleased to be able to bring this exciting treatment modality to our sarcoma patients." About ADCE-D01 ADCE-D01 is an antibody-drug conjugate (ADC) targeting the uPARAP receptor. uPARAP is a continuously recycling endocytic receptor involved in collagen homeostasis. uPARAP exhibits a restricted expression profile in healthy tissues but is highly upregulated in multiple mesenchymal cancers, including STS, bone sarcoma, GIST, as well as mesothelioma and glioblastoma. ADCE-D01 is a first-in-class pan-mesenchymal cancer targeting ADC in phase 1/2 clinical development. Adcendo is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. Led by a team of industry veterans with a track record of advancing multiple ADCs to approval, Adcendo integrates novel targets, optimized linker-payload combinations, and a rationally designed development strategy to drive next-generation cancer therapies. For further information, please visit or follow the company on LinkedIn.
